Intact Medical closed a $4 million equity funding round in support of its breast biopsy systems, the company revealed in regulatory filings.
The Framingham, Mass.-based device maker listed 11 unnamed investors who participated in the round.
Intact is developing a breast biopsy device, called the Breast Lesion Excision System, which these funds will benefit. The device uses RF energy through a minimally invasive procedure to withdraw sample breast tissue.
The privately held company was founded in 1998 and in 2001 won FDA approval to market its technology for biopsy and excision of benign lesions. The FDA in 2005 expanded the label to include its use "to obtain tissue samples for histologic examination with partial or complete removal of an imaged abnormality, or partial removal of a palpable abnormality that has been classified as benign," according to company documents.
